Jokin Del Amo

Title: Jokin Del Amo: Innovator in Prostate Cancer Prognosis

Introduction

Jokin Del Amo is a notable inventor based in Getxo, Spain. He has made significant contributions to the field of medical technology, particularly in the area of prostate cancer prognosis. His innovative work focuses on improving the accuracy of predicting cancer recurrence in patients.

Latest Patents

Jokin Del Amo holds a patent for a prognostic method that aids in forecasting the recurrence of prostate cancer (PCa) in subjects following prostatectomy. This method utilizes the outcomes of selected single nucleotide polymorphisms (SNPs) along with clinical variables. Additionally, his patent includes a method for genotyping PCa-associated genetic variations, which involves the use of a DNA microarray. The microarray is designed for application in the described methods, showcasing his commitment to advancing cancer diagnostics.

Career Highlights

Del Amo is associated with Progenika Biopharma S.A., a company dedicated to developing innovative solutions in the field of personalized medicine. His work at Progenika Biopharma has positioned him as a key player in the biotechnology sector, contributing to advancements that can significantly impact patient care.

Collaborations

Throughout his career, Jokin Del Amo has collaborated with esteemed colleagues, including Laureano Simón Buela and Antonio Martínez Martínez. These partnerships have fostered a collaborative environment that enhances research and development efforts in the medical field.

Conclusion

Jokin Del Amo's contributions to prostate cancer prognosis through his innovative patent demonstrate his dedication to improving patient outcomes. His work at Progenika Biopharma and collaborations with fellow researchers highlight the importance of teamwork in advancing medical technology.